Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study by Sheehan, R et al.
the bmj | BMJ   2015;101hh; 26 | doi1 02.00;26/bmj.hh; 26
RESEARCH
1
open access
1Division of Psychiatry, 
University College London, 
London W1T 7NF, UK
2Research Department of 
Primary Care and Population 
Health, University College 
London (Royal Free Campus), 
London NW3 2PF, UK
Correspondence to:  
Rory Sheehan  
r.sheehan@ucl.ac.uk
Additional material is published 
online only. To view please visit 
the journal online (http://dx.doi.
org/10.1136/bmj.h4326)
Cite this as: BMJ 2015;351:h4326
doi: 10.1136/bmj.h4326
Accepted: 31 Jul 2015
Mental illness, challenging behaviour, and psychotropic drug 
prescribing in people with intellectual disability: UK population 
based cohort study
Rory Sheehan,1 Angela Hassiotis,1 Kate Walters,2 David Osborn,1 André Strydom,1 Laura Horsfall2 
ABSTRACT
ObjeCtives
To describe the incidence of recorded mental illness 
and challenging behaviour in people with intellectual 
disability in UK primary care and to explore the 
prescription of psychotropic drugs in this group.
Design
Cohort study.
setting
571 general practices contributing data to The Health 
Improvement Network clinical database.
PartiCiPants
33 016 adults (58% male) with intellectual disability 
who contributed 211 793 person years’ data.
Main OutCOMe Measures
Existing and new records of mental illness, challenging 
behaviour, and psychotropic drug prescription.
results
21% (7065) of the cohort had a record of mental illness 
at study entry, 25% (8300) had a record of challenging 
behaviour, and 49% (16 242) had a record of 
prescription of psychotropic drugs. During follow-up, 
the rate of new cases of mental illness in people 
without a history at cohort entry was 262 (95% 
confidence interval 254 to 271) per 10 000 person years 
and the rate of challenging behaviour was 239 (231 to 
247) per 10 000 person years. The rate of new 
psychotropic drug prescription in those without a 
previous history of psychotropic drug treatment was 
518 (503 to 533) per 10 000 person years. Rates of new 
recording of severe mental illness declined by 5% 
(95% confidence interval 3% to 7%) per year 
(P<0.001), and new prescriptions of antipsychotics 
declined by 4% (3% to 5%) per year P<0.001) between 
1999 and 2013. New prescriptions of mood stabilisers 
also decreased significantly. The rate of new 
antipsychotic prescribing was significantly higher in 
people with challenging behaviour (incidence rate 
ratio 2.08, 95% confidence interval 1.90 to 2.27; 
P<0.001), autism (1.79, 1.56 to 2.04; P<0.001), and 
dementia (1.42, 1.12 to 1.81; P<0.003) and in those of 
older age, after control for other sociodemographic 
factors and comorbidity.
COnClusiOns
The proportion of people with intellectual disability 
who have been treated with psychotropic drugs far 
exceeds the proportion with recorded mental illness. 
Antipsychotics are often prescribed to people without 
recorded severe mental illness but who have a record 
of challenging behaviour. The findings suggest that 
changes are needed in the prescribing of 
psychotropics for people with intellectual disability. 
More evidence is needed of the efficacy and safety of 
psychotropic drugs in this group, particularly when 
they are used for challenging behaviour.
Introduction
Approximately 1% of the population have intellectual 
disability, defined as a significant deficit in cognitive and 
adaptive function with onset during the developmental 
period.1  People with intellectual disability develop men-
tal illness at rates similar to or higher than the general 
population,2  but atypical presentations, deficits in com-
munication and health literacy, and difficulties in access-
ing services might mean that mental illness in people 
with intellectual disability is under-recorded. In addi-
tion, a significant proportion of people with intellectual 
disability display challenging behaviour, also known as 
behaviour that challenges or problem behaviours—that 
is, behaviour of an intensity, frequency, or duration that 
threatens the physical safety of the person or others or 
restricts access to community facilities.3
Concern has existed for many years that psychotropic 
drugs in general and antipsychotics in particular are 
overused in people with intellectual disability and might 
often be prescribed for challenging behaviour in itself 
rather than for diagnosed mental illness, despite lack of 
evidence of efficacy.4-7  However, obtaining accurate esti-
mates of the rates of psychotropic drug use in this group 
has been difficult, and the applicability of existing liter-
ature is limited by inconsistent definitions of intellectual 
disability and use of small or highly selected samples. 
Despite the evident interest in this topic from policy and 
care perspectives,8 no comprehensive examination of 
WhAT IS AlReAdy knoWn on ThIS TopIC
People with intellectual disability develop severe mental illness at higher rates than 
do the general population and may show challenging behaviour
Antipsychotic drugs might be prescribed to people with intellectual disability to 
manage challenging behaviour, despite lack of evidence and the risk of adverse 
side effects
The perceived overuse of psychotropic drugs in people with intellectual disability 
has been widely criticised
WhAT ThIS STudy AddS
More than a third of people with intellectual disability have a primary care record of 
challenging behaviour
Prescription of antipsychotic drugs in UK primary care is disproportionate to the 
level of recorded severe mental illness and is associated with the presence of 
challenging behaviour, older age, and diagnoses of autism and dementia
Findings highlight the need for an improved evidence base for use of drugs and 
optimisation of drug treatment in people with intellectual disability
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psychotropic drug use in adults with intellectual disabil-
ity in UK primary care has been carried out, and findings 
from other countries may not be generalisable given dif-
ferences in healthcare practice and provision.
Evidence suggests that use of psychotropic drugs in 
the general population has increased consistently over 
the past several years,9 10 but little research has explored 
longitudinal trends in prescribing of psychotropics to 
people with intellectual disability. Whether deinstitu-
tionalisation, increased awareness of drugs’ side 
effects, and attempts to reduce inappropriate drug 
treatment in people with intellectual disability by the 
introduction of prescribing guidelines have changed 
prescribing practice remains unclear.11
Using a very large and representative sample of ano-
nymised primary healthcare records from the United 
Kingdom, we have described the rates of recorded men-
tal illness, challenging behaviour, and use of psycho-
tropic drugs in people with intellectual disability in the 
primary care setting. We also report the patterns of pre-
scribing of psychotropics over the past 15 years and the 
factors associated with prescription of antipsychotics.
Methods
Data source
The Health Improvement Network (THIN) is a large pri-
mary care database that contains the electronic health 
records of more than 3.7 million active patients in 571 
general practices (www.epic-uk.org/our-data/our-data.
shtml). The patients included are representative of the 
UK population as a whole in terms of age, sex, medical 
conditions, and death rates.12 13 Data from THIN are ano-
nymised at source and collated by IMS Health before 
being made available for research. 
Ninety eight per cent of the UK population are regis-
tered with a general practitioner, who acts as the gate-
keeper to healthcare services for all patients, regardless 
of level of disability or living arrangements.14  General 
practitioners can refer complex cases to hospital based 
specialists, such as psychiatrists, who make an assess-
ment and offer advice on further investigation or man-
agement. If drug treatment is indicated, this is usually 
prescribed by general practitioners, who hold prescrib-
ing budgets. Clinicians or practice staff enter informa-
tion from the general practice consultation or secondary 
care specialist into a computerised system as Read 
codes, standardised clinical terms based on a hierarchi-
cal system.15 The general practice record thus contains 
a comprehensive and accurate longitudinal record of a 
person’s clinical encounters and their outcomes.
The THIN database contains symptoms, diagnoses, 
referrals to secondary care, and a record of treatments 
and of prescriptions, which are classified according to 
chapters in the British National Formulary. THIN is well 
suited to studying drug prescription, as clinicians must 
code the prescribed drug before the prescription can be 
issued, so all prescriptions issued in primary care are 
recorded. Recording of illness, including for mental and 
developmental disorders, has been shown to be  accurate 
in electronic primary care records, and estimates of dis-
ease prevalence closely approximate those determined 
by other means, making the data suitable for epidemio-
logical research.16  Patients’ demographic information 
and a measure of social deprivation (the Townsend 
score), which is a composite score in fifths based on Cen-
sus recording of unemployment, car ownership, home 
ownership, and overcrowding, is also recorded.17
study cohort
The study cohort included adults with intellectual dis-
ability drawn from UK primary care. General practi-
tioners have been incentivised to keep a register of all 
patients with known intellectual disability since 2007 
as part of the quality and outcomes framework (QOF) 
scheme (http://qof.hscic.gov.uk/). We used established 
methods to create our intellectual disability code list,18 
which was based on that used in a previous study.19  We 
included people with a QOF intellectual disability code 
as well as those who were not identified by the QOF 
scheme but who had a Read code anywhere in their 
record signalling intellectual disability or a condition 
associated with intellectual disability in more than 50% 
cases. This has been shown to substantially increase 
the detection of people with intellectual disability in 
the THIN database.19  Before extracting the cohort for 
this study and applying the age exclusions, we used the 
code list to estimate the prevalence of intellectual dis-
ability in the 3.7 million active patients in THIN. We 
identified 32 306 active adults with intellectual disabil-
ity, or 0.9%, which is comparable to population preva-
lence estimates of intellectual disability at 1%.20
People in the cohort contributed different lengths of fol-
low-up to the study. The date of entry into the cohort for 
each person was taken as the latest of the date of registra-
tion at a practice contributing to THIN plus one year to 
account for the transfer of historical information,21  the 
year they turned 18, the start of the study period (1 January 
1999), and the date their general practice was recording 
data consistent with the two key indicators that help to 
affirm the quality of the entered data (acceptable mortality 
reporting and acceptable computer usage).22 23 The end 
date for each person was the earliest of the date that they 
left the practice, the date they turned 100 years old, or the 
end of the study period (31 December 2013). We excluded 
people who contributed less than 12 months’ data to THIN, 
as these records often include temporary and visiting 
patients for whom the quality of data recording is poor.
Outcomes of interest
Neuropsychiatric diagnoses
We interrogated the record of each person who met the 
inclusion criteria for Read codes for mental illness. We 
divided mental illness into severe mental illness (schizo-
phrenia, bipolar disorder, other psychosis), depression 
(including mixed depression-anxiety), and anxiety. If a 
person had a record of two of the disorders within the 
severe mental illness category (such as a code for schizo-
phrenia and another for bipolar  disorder), for the pur-
pose of describing the case mix at cohort entry we used 
a hierarchical system whereby the schizophrenia diag-
nosis was taken in preference to bipolar disorder, and 
this in turn was used in preference to the group of “other 
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psychosis.” We also included code lists for dementia, 
autism, and epilepsy to examine the relation with chal-
lenging behaviour and prescribing of antipsychotic 
drugs. We determined neuropsychiatric diagnoses by 
screening people’s records for relevant codes that our 
team has used to identify these conditions in previous 
studies. For conditions that are generally present from a 
young age, in this case autism and epilepsy, we took a 
code entered anywhere in the record as evidence of the 
condition at cohort entry. Mental illness, epilepsy, and 
dementia are also included in the QOF scheme and 
should be reliably recorded by general practitioners.
Challenging behaviour
We defined challenging behaviour with reference to the 
National Institute for Health and Care Excellence’s con-
ceptualisation of the term and included the following 
behaviours: aggression, self injury, stereotypic 
behaviour, agitation, disruptive or destructive acts, 
withdrawn behaviour, arson, and sexual misconduct.24 
We constructed a list of Read codes describing these 
behaviours by screening the full Read code dictionary 
for potentially suitable terms. After discussion and on 
the basis of clinical experience of managing patients 
with intellectual disability and knowledge of the liter-
ature, we also included codes for sleep disturbance.25 
The list was then refined in an iterative process through 
consultation between four clinical academics (three 
psychiatrists specialising in intellectual disability and 
one general practitioner); the final list contained more 
than 200 codes (web appendix A). We recorded people 
as having a history of challenging behaviour at cohort 
entry if at least one of any of these codes was present in 
their record and recorded them as having incident 
challenging behaviour if a code was added during fol-
low-up. To assess the performance of the challenging 
behaviour code list, we examined the variable in rela-
tion to factors known to be associated with challenging 
behaviour in people with intellectual disability, includ-
ing the presence of other neuropsychiatric diagnoses. 
We also examined the challenging behaviour code list 
in relation to severity of intellectual disability in the 
subset for which this information was coded as mild, 
moderate, severe, or profound and also compared 
recording of challenging behaviour in people with 
Down’s syndrome with those with autism.
Prescription of psychotropic drugs
We divided psychotropic drugs into several classes 
according to British National Formulary sub-chapter: 
antipsychotics (including first and second generation 
agents), antidepressants, mood stabilisers, anxiolyt-
ics and hypnotics (including benzodiazepines), 
antidementia drugs, and drugs for attention-deficit/
hyperactivity disorder.
statistical analysis
We used multivariable mixed Poisson regression to 
examine time trends of recording of mental illness and 
new prescriptions for psychotropic drugs in people with-
out a history at cohort entry and to calculate incidence 
rate ratios adjusted for any temporal changes in age and 
sex. We included general practice as a random effect to 
account for any data clustering. If people received a new 
prescription for a drug after cohort entry (that is, during 
follow-up) we considered them to be no longer at risk for 
that drug prescription and removed them from the 
cohort. To examine the possibility of non-linear time 
trends, year was initially modelled as a continuous 
 variable and we then used the likelihood ratio test to 
compared this with a model in which year was entered as 
a categorical variable. A significant test result suggests 
that the categorical model is a better fit to the data and a 
linear time trend assumption may not be appropriate.
We also used multivariable mixed Poisson regression 
to examine factors associated with new records of chal-
lenging behaviour and new prescription of antipsy-
chotic drugs in people without a history at cohort entry. 
We investigated multiplicative interactions between 
sex, challenging behaviour, and prescription of anti-
psychotics as a pre-specified hypothesis by including 
the appropriate interaction terms in the regression 
model. In the regression model examining new pre-
scriptions of antipsychotics, we tested the influence of 
excluding sleep codes from the challenging behaviour 
code list as a sensitivity analysis. We used Wald tests to 
assess overall significance for categorical variables and 
categorical interaction terms. We considered a P value 
of 0.05 to be statistically significant (two tailed) and 
used Stata version 13 for all analyses.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures; nor were they involved in 
the design and implementation of the study. We plan to 
work with our local service user research group (the 
Camden Advocacy Project) to prepare accessible (easy 
read) versions of the abstract and manuscript content, 
which will be widely disseminated.
Results
Characteristics of cohort
In total, 33 016 people with a record of intellectual disabil-
ity met the inclusion criteria. Table 1 gives the baseline 
characteristics of the cohort. Fifty eight per cent were 
male, and the average age at study entry was 36.3 years. 
Median follow-up time was 5.5 (interquartile range 2.2-11.5) 
years. Overall, 211 793 person years’ data were collected.
recording of mental illness
In total, 21% of the cohort had a record of mental illness 
at study entry, including 7% with a record of severe 
mental illness (schizophrenia 4%, bipolar disorder 1%, 
other psychosis 2%) (table 1 ). The incidence of new 
records of mental illness was 262 (95% confidence 
 interval 254 to 271) per 10 000 person years during fol-
low-up (table 2 ). New records of depression were most 
frequently recorded. By the end of the study period, the 
proportion of people with a record of mental illness (not 
including those with only challenging behaviour) at 
any point in their primary care notes was 34% (7065 
at  baseline and 3998 during follow-up), and the 
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 proportion with a record of severe mental illness was 
9% (tables 1  and 2).
Analysis of time trends in the recording of severe men-
tal illness showed a gradual decline in the rate of record-
ing by 5% (95% confidence interval 3% to 7%)  per year 
between 1999 and 2013 (P<0.001), after adjustment for 
changes in age and sex of the cohort (fig 1). Rates of 
recording of depression and anxiety did not change.
Challenging behaviour
In total, 8300 (25%) people had a history of challenging 
behaviour at study entry. The rate of new cases of 
 challenging behaviour during follow-up in those without 
a previous history at cohort entry was 239 (231 to 247) per 
10 000 person years. By the end of the study period, 36% 
of people in the cohort had a record of challenging 
behaviour in their electronic health record (8300 at base-
line and 3615 during follow-up) (tables 1  and 2). The most 
common Read codes in the challenging behaviour code 
list found in the cohort were “behavioural problem,” 
“behaviour disorder,” “behavioural problems,” “agi-
tated,” and “agitated—symptom.” Codes describing spe-
cific behaviours were used less frequently. Excluding sleep 
codes reduced the number with challenging behaviour at 
baseline to 7531 and the rate of new records during fol-
low-up to 175 (169 to 182) per 10 000 person years.
The median number of Read codes for challenging 
behaviour in people with a record of challenging 
behaviour (including sleep codes) was 2 (interquartile 
range 1-4). New records of challenging behaviour were 
significantly more common in people older than 50 
years and in those with mental illness (including severe 
mental illness, depression, and anxiety), autism, 
dementia, and epilepsy (table 3 ). We found no associa-
tion of new recording of challenging behaviour with sex 
or social deprivation. New recording of challenging 
behaviour showed a non-significant downward trend 
during the study period (fig 1). In separate analyses, we 
identified a positive association between challenging 
behaviour and degree of intellectual disability in the 
5332 people for whom information on severity had been 
coded; challenging behaviour was three times more 
common in people with profound intellectual disability 
than in those described as having mild intellectual dis-
ability (incidence rate ratio 2.97 (95% confidence inter-
val 2.09 to 4.21; P<0.001); data not shown). Compared 
with people with Down’s syndrome, those coded as 
having autism were more than twice as likely to be 
coded as having challenging behaviour (incidence rate 
ratio 2.15, 1.87 to 2.48; p<0.001; data not shown).
Prescription of psychotropic drugs
A history of prescription of psychotropic drugs was pres-
ent in 49% of the cohort at study entry, and 63% had a 
record by the end of data collection. The incidence rate 
of new prescription of any psychotropic drugs over the 
follow-up period was 518 (503 to 533) per 10 000 person 
years. The most common class of drugs to be prescribed 
was anxiolytics/hypnotics, followed by antidepressants, 
antipsychotics, and mood stabilisers. The rate of pre-
scription of antidementia drugs and drugs for atten-
tion-deficit/hyperactivity disorder was much lower at 10 
(8 to 11) per 10 000 person years and 2 (2 to 3) per 10 000 
table 1 | Characteristics of cohort at study entry. values are numbers (percentages) 
unless stated otherwise
Characteristic value (n=33 016)
Mean (SD) age, years 36.3 (16.4)
Median (interquartile range) follow-up time, years 5.5 (2.2-11.5)
Male sex 19 139 (58)
Autism 4925 (15)
Epilepsy 7517 (23)
Dementia 319 (1)
History of mental illness 7065 (21)
 Severe mental illness 2364 (7)
  Schizophrenia 1313 (4)
  Bipolar disorder 439 (1)
  Psychosis, other 612 (2)
 Depression (including mixed anxiety-depression) 3620 (11)
 Anxiety 1845 (6)
 History of challenging behaviour 8300 (25)
History of psychotropic drug prescription 16 242 (49)
 Antipsychotic 7028 (21)
 Antidepressant 6614 (20)
 Mood stabiliser 6698 (20)
 Anxiolytic/hypnotic 7152 (22)
 Antidementia drugs 254 (0)
 Drugs for attention-deficit/hyperactivity disorder 623 (2)
table 2 | incidence of recorded mental illness, challenging behaviour, and psychotropic 
drug prescription in adults with intellectual disability in uK primary care, 1999-2013 
variable no of events
no of patient 
years (×10 000)
incidence per 10 000 
patient years (95% Ci)
Any mental illness 3998 15.2 262 (254 to 271)
Severe mental illness 617 19.5 32 (29 to 34)
Depression 3054 17.9 171 (165 to 177)
Anxiety 2512 18.0 139 (134 to 145)
Challenging behaviour 3615 15.1 239 (231 to 247)
Any psychotropic drug 4640 9.0 518 (503 to 533)
Antipsychotic 2107 15.9 132 (127 to 138)
Antidepressant 4733 15.1 313 (305 to 323)
Mood stabiliser 1337 16.3 82 (78 to 87)
Anxiolytic/hypnotic 4835 14.7 330 (321 to 339)
Antidementia drugs 204 21.1 10 (8 to 11)
Drugs for attention-deficit/
hyperactivity disorder
52 21.0 2 (2 to 3)
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Fig 1 | time trends in new recording of mental illness and 
challenging behaviour in adults with intellectual disability 
in uK primary care, 1999-2013
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person years, respectively, which precluded further 
investigation of time trends in their prescription.
Prescription of antipsychotics fell by 4% (3% to 5%; 
P<0.001) per year over the course of the study period, 
and the prescription of mood stabilisers also decreased 
by 4% (3% to 6%; P<0.001) per year. We found no signif-
icant time trends in the prescription of other classes of 
psychotropic drugs (fig 2). Prescription of antidepres-
sants fell significantly in 2005, but rates of prescription 
in 2013 were similar to those seen at the start of the 
observation period in 1999.
New prescriptions for antipsychotics were signifi-
cantly more common in older people and in those with 
a record of challenging behaviour, severe mental ill-
ness, depression, anxiety, autism, dementia, and epi-
lepsy (tables 4  and 5). We found no association of new 
prescription of antipsychotics with sex or level of social 
deprivation. People with a record of challenging 
behaviour were more than twice as likely to receive a 
prescription for antipsychotics compared with those 
without a record of challenging behaviour (incidence 
rate ratio 2.08, 1.90 to 2.27; P<0.001) after control for 
neuropsychiatric diagnoses. Excluding sleep codes 
from the definition of challenging behaviour as a sensi-
tivity analysis increased the magnitude of the associa-
tion with prescribing of antipsychotics (incidence rate 
ratio 3.49, 3.19 to 3.82; P<0.001).
Figure 3 shows the overlap between people with a 
record of severe mental illness, challenging behaviour, 
and prescription of antipsychotics. Of 9135 peoples 
treated with antipsychotic drugs by the end of  follow-up, 
6503 (71%) did not have a record of severe mental illness. 
Of the 11 915 with a record of challenging behaviour, 5562 
(47%) had received antipsychotic drugs, whereas only 
1421 (12%) had a record of severe mental illness. Of those 
with a record of prescription of antipsychotics, 2362 (26%) 
did not have a record of severe mental illness or challeng-
ing behaviour. Further detail of the overlap between chal-
lenging behaviour, prescription of antipsychotics, and 
neuropsychiatric diagnoses is given in web appendix B.
discussion
To the best of our knowledge, this study represents the 
largest and most comprehensive analysis of the associa-
tions between mental illness, challenging behaviour, 
and prescribing of psychotropic drugs in people with 
intellectual disability. We found that more than a third 
of people with intellectual disability had a record of 
mental illness, including almost 1 in 10 who had a record 
of severe mental illness. Challenging behaviour was also 
commonly recorded by general practitioners. The pro-
portion of people who had been treated with psychotro-
pic drugs was much greater than the recorded rate of 
psychiatric morbidity. More than two thirds of people 
had a record of prescription of any psychotropic drug, 
and more than a quarter had received an antipsychotic. 
Most antipsychotics were prescribed to people without a 
record of severe mental illness, despite financial incen-
tives to record mental illness via the QOF scheme.
Challenging behaviour was independently associated 
with prescription of antipsychotics after adjustment for 
neuropsychiatric diagnoses, suggesting that these drugs 
are being used to manage challenging behaviour in pri-
mary care in some cases. Autism, dementia, and older 
age were also independently associated with antipsy-
chotic use in people with intellectual disability.
We found that the recording of new severe mental ill-
ness and the prescription of antipsychotics and mood 
table 3 | associations with new recording of challenging behaviour in adults with 
intellectual disability in uK primary care, 1999-2013
Factor
rate (per 10 000 patient 
years) (95% Ci)
incidence rate ratio* 
(95% Ci) P value
Sex:
 Male 243 (231 to 255) 1 (reference)
NS
 Female 235 (225 to 246) 0.97 (0.91 to 1.04)
Age group, years:
 18-29 218 (204 to 234) 1 (reference)
<0.001
 30-39 220 (204 to 237) 1 (0.90 to 1.11)
 40-49 226 (211 to 242) 1.01 (0.91 to 1.12)
 50-59 260 (241 to 282) 1.13 (1.02 to 1.26)
 60-69 286 (259 to 316) 1.27 (1.12 to 1.45)
 70-79 304 (262 to 351) 1.40 (1.18 to 1.65)
 ≥80 382 (302 to 483) 1.78 (1.38 to 2.30)
Townsend deprivation fifth:
 1 (least deprived) 230 (212 to 251) 1 (reference)
NS
 2 247 (229 to 267) 1.06 (0.95 to 1.20)
 3 226 (210 to 244) 1.02 (0.90 to 1.14)
 4 225 (210 to 242) 0.97 (0.87 to 1.10)
 5 (most deprived) 264 (246 to 282) 1.10 (0.98 to 1.25)
 Missing 247 (212 to 288) 1.08 (0.89 to 1.32)
Neuropsychiatric diagnosis:
 No severe mental illness 224 (216 to 232) 1 (reference)
<0.001
 Severe mental illness 442 (403 to 484) 1.69 (1.53 to 1.88)
 No depression 201 (193 to 209) 1 (reference)
<0.001
 Depression 399 (376 to 423) 1.71 (1.58 to 1.86)
 No anxiety 209 (201 to 217) 1 (reference)
<0.001
 Anxiety 384 (360 to 409) 1.44 (1.33 to 1.57)
 No autism 227 (219 to 235) 1 (reference)
<0.001
 Autism 380 (346 to 418) 1.83 (1.64 to 2.03)
 No dementia 233 (225-240) 1 (reference)
<0.001
 Dementia 482 (416 to 558) 1.71 (1.45 to 2.01)
 No epilepsy 225 (217 to 234) 1 (reference)
<0.001
 Epilepsy 287 (270 to 306) 1.41 (1.30 to 1.52)
NS=not significant.
*Adjusted for age, sex, Townsend deprivation fifth, neuropsychiatric diagnoses, and year of study entry.
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Fig 2 | time trends in new prescriptions of psychotropic 
drugs in adults with intellectual disability in uK primary 
care, 1999-2013
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stabilisers to people with intellectual disability in pri-
mary care decreased consistently over the past 15 years, 
whereas rates of common mental disorders and chal-
lenging behaviour, along with other classes of psycho-
tropic drugs, did not change.
Comparison with other studies
We used routine primary care records to determine the 
incidence of newly recorded mental illness and challeng-
ing behaviour in people with intellectual disability, so 
our results are not directly comparable with previous epi-
demiological studies, most of which report the point 
prevalence of morbidity after direct assessment of partic-
ipants’ mental state. Such studies consistently report 
high rates of severe mental illness in people with intellec-
tual disability.26  27  The incidence of newly recorded 
severe mental illness that we found in people with intel-
lectual disability (32 per 10 000 person years) is substan-
tially higher than that in the general population (reported 
by a different study but derived from the same data-
base28 ), suggesting that severe mental illness is generally 
well recognised in people with intellectual disability in 
primary care. In contrast, we did not find increased rates 
of new recording of anxiety and depression in people 
with intellectual disability over the study period com-
pared with the general population,29  30  despite evidence 
that they are likely to be at higher risk of developing both 
conditions.31  32 Our results may therefore indicate 
under-recognition of depression and anxiety in people 
with intellectual disability in primary care.
Longitudinal trends in recording of mental illness in 
primary care have not previously been studied in people 
with intellectual disability, and it is interesting that the 
rate of recording of new cases of severe mental illness 
steadily decreased. Several possible explanations for this 
observation exist. It might mirror a trend highlighted in 
the non-intellectual disability population whereby clini-
cians in primary care increasingly use Read codes for 
symptoms rather than diagnoses to record mental ill-
ness.29  30 The symptoms would not be recognised in our 
code lists as severe mental illness. Alternatively, the 
trend may be due to increasing under-recognition of 
severe mental illness in people with intellectual disabil-
ity, although the relatively high crude incidence rates we 
found suggest that this is not the case. Another explana-
tion would be that the true incidence of severe mental 
illness is falling, possibly owing to improvements in pub-
lic health that have reduced precipitating factors.
This is the first study of which we are aware that has 
quantified challenging behaviour in primary care by 
using routinely collected health data. We found that 
challenging behaviour was recorded in more than a 
third of people, a rate that is higher than the 10-15% 
 previously reported in people with intellectual disabil-
ity.3  However, considerable discrepancy exists in previ-
ously reported rates of challenging behaviour in people 
with intellectual disability owing to differences in defi-
nitions and groups studied. The expected associations 
of challenging behaviour with degree of intellectual 
disability, autism, mental illness, and dementia were 
replicated in our study,33-37  and incidence rate ratios for 
each were similar to those reported by a recent popula-
tion study in Sweden,38  which adds legitimacy to the 
code list we devised. Furthermore, the positive associa-
tions between challenging behaviour and degree of 
intellectual disability, as well as the higher rates in peo-
ple with autism compared with Down’s syndrome, were 
as expected. We found an unexpected increase in new 
cases of challenging behaviour with age,3 33 38 39  which 
persisted even when we controlled for increased record-
ing of dementia among the older population. Dementia 
can be difficult to diagnose in people with intellectual 
disability and may be under-recognised;40 if all true 
cases of dementia were coded, the association of chal-
lenging behaviour with age may be less marked. 
Another explanation is that the code list for challenging 
behaviour we devised might include codes that are pref-
erentially applied to the older population.
At 132 per 10 000 person years, the rate of prescrip-
tion of antipsychotics in people with intellectual 
 disability is almost twice that of the general population 
(70/10 000 person years for women and 61/10 000 per-
son years for men, from previously published research 
using THIN data41). Approximately 50% of prescriptions 
table 4 | incidence of new prescription of antipsychotic 
drugs in adults with intellectual disability in uK primary 
care, 1999-2013, by sociodemographic factors and 
neuropsychiatric diagnosis
Factor
rate (per 10 000 patient 
years) (95% Ci)
Sex:
 Male 134 (125 to 142)
 Female 131 (124 to 139)
Age group, years:
 18-29 130 (120 to 141)
 30-39 122 (111 to 134)
 40-49 118 (107 to 130)
 50-59 132 (118 to 147)
 60-69 149 (129 to 173)
 70-79 213 (177 to 257)
 ≥80 305 (236 to 394)
Townsend deprivation fifth:
 1 (least deprived) 131 (118 to 147)
 2 135 (121 to 149)
 3 136 (124 to 149)
 4 133 (122 to 146)
 5 (most deprived) 122 (110 to 134)
 Missing 154 (127 to 186)
Neuropsychiatric diagnosis:
 Challenging behaviour 237 (222 to 252)
 No challenging behaviour 96 (90 to 101)
 Severe mental illness 1005 (890 to 1135)
 No severe mental illness 118 (112 to 123)
 Depression 250 (233 to 269)
 No depression 104 (99 to 110)
 Anxiety 246 (228 to 265)
 No anxiety 109 (104 to 115)
 Autism 232 (207 to 259)
 No autism 123 (118 to 129)
 Dementia 257 (208 to 318)
 No dementia 129 (124 to 135)
 Epilepsy 138 (126 to 150)
 No epilepsy 131 (124 to 137)
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for antipsychotics in primary care to people without 
intellectual disability are given in the absence of a 
record of severe mental illness,41 and our findings show 
an even higher proportion (71%) in those with intellec-
tual disability. This finding is comparable to that of a 
Norwegian study, which reported that only 24% of anti-
psychotics prescribed to a group of people with intellec-
tual disability were indicated by a diagnosis of 
psychosis,42 and other European work showing that 
most antipsychotics prescribed to people with intel-
lectual disability are given to manage behavioural 
problems rather than mental illness.43 However, the 
results contrast with a more recent North American sur-
vey, which reported that only a minority of antipsy-
chotic drugs were prescribed to people without a formal 
psychiatric diagnosis.44 That prescription of antipsy-
chotic and mood stabilising drugs in people with intel-
lectual disability reduced consistently over the past 15 
years is at variance with trends in the use of psychotro-
pic drugs reported in the general population and among 
adults with intellectual disability in Taiwan.9 10 45  The 
fall in prescription rates that we have shown might be 
secondary to reduced incidence or recognition of severe 
mental illness or might reflect a gradual change in prac-
tice away from using psychotropic drugs as criticism of 
perceived overuse has intensified.46 47
strengths and limitations
The THIN database is a record of real life clinical practice 
in UK primary care and thus provides an accurate and 
representative insight into contemporary care. Use of 
routinely collected data has advantages for research in 
people with intellectual disability, who may be difficult 
to reach and enrol in clinical trials or observational stud-
ies.48 As well as small sample sizes, active recruitment 
may result in an over-representation of higher socioeco-
nomic groups or people with more engaged carers, which 
may not be representative of the general intellectual dis-
ability population. Furthermore, investigations in the 
secondary care setting may tend to enrol more severe 
cases with more challenging behavioural and psychiatric 
problems and thus lead to overestimates of the use of 
psychotropic drugs in people with intellectual disability.
Many of the limitations of the study are inherent to 
the use of routine health data. Using our code list, we 
estimated a prevalence of intellectual disability of 0.9% 
in THIN data, which is similar to population estimates.20 
The slightly lower prevalence in our data may reflect the 
exclusion of young people, the underdiagnosis of 
milder cases by general practitioners, or the inclusion 
of lower income countries in the meta-analysis. We may 
have missed a small proportion of mild cases of 
 intellectual disability, which if included and assuming 
that the behavioural problems in this group are gener-
ally less challenging, may have reduced the magnitude 
of the association with prescription of antipsychotics.
The results are of recorded diagnoses, which may not 
correspond to the true rate of illness in the population. 
Some diagnoses may have been entered in the free text of 
the computer system, which we did not interrogate. We 
restricted our mental illness code lists to the most com-
mon mental disorders and excluded categories such as 
personality disorder and substance misuse; further work 
is necessary to report on a wider range of illnesses. The 
challenging behaviour code list has not been externally 
validated, and we cannot report its sensitivity or specific-
ity. However, it showed the expected associations with 
conditions known to increase the risk of challenging 
behaviour and is therefore likely to adequately represent 
the concept. Certain characteristics, such as degree of 
intellectual disability, are not always well recorded in 
THIN, and we have not been able to extend our 
table 5 | associations with new antipsychotic drug prescription in adults with 
intellectual disability in uK primary care, 1999-2013
Factor irr* (95% Ci) P value irr† (95% Ci) P value
Sex:
 Male 1 (reference)
NS
1 (reference)
NS
 Female 1.04 (0.95 to 1.12) 1.01 (0.93 to 1.11)
Age group, years:
 18-29 1 (reference)
<0.001
1 (reference)
<0.001
 30-39 0.95 (0.84 to 1.07) 0.99 (0.88 to 1.13)
 40-49 0.91 (0.80 to 1.03) 0.96 (0.85 to 1.10)
 50-59 1.01 (0.88 to 1.16) 1.08 (0.93 to 1.25)
 60-69 1.14 (0.97 to 1.35) 1.32 (1.11 to 1.57)
 70-79 1.65 (1.34 to 2.02) 1.81 (1.46 to 2.24)
 ≥80 2.39 (1.82 to 3.13) 2.72 (2.06 to 3.61)
Townsend deprivation fifth:
 1 (least deprived) 1 (reference)
NS
1 (baseline)
NS
 2 1.02 (0.88 to 1.19) 0.96 (0.82 to 1.12)
 3 1.03 (0.89 to 1.19) 0.97 (0.83 to 1.13)
 4 1.03 (0.89 to 1.19) 0.94 (0.81 to 1.09)
 5 (most deprived) 0.94 (0.81 to 1.10) 0.81 (0.69 to 0.95)
 Missing 1.21 (0.96 to 1.52) 1.1 (0.87 to 1.39)
Neuropsychiatric diagnosis:
 Severe mental illness 8.87 (7.76 to 10.15) <0.001 6.69 (5.83 to 7.68) <0.001
 Challenging behaviour 2.51 (2.30 to 2.76) <0.001 2.08 (1.90 to 2.27) <0.001
 Autism 1.87 (1.66 to 2.12) <0.001 1.79 (1.56 to 2.04) <0.001
 Depression 2.49 (2.27 to 2.72) <0.001 1.79 (1.62 to 1.98) <0.001
 Anxiety 2.36 (2.15 to 2.60) <0.001 1.63 (1.47 to 1.81) <0.001
 Dementia 1.91 (1.54 to 2.40) 0.003 1.42 (1.12 to 1.81) 0.003
 Epilepsy 1.04 (0.94 to 1.15) NS 1.15 (1.04 to 1.28) 0.007
IRR=incidence rate ration; NS=not significant.
*Univariable analysis.
†Multivariable analysis adjusted for age, sex, Townsend deprivation fifth, neuropsychiatric diagnoses, and year 
of study entry.
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Fig 3 | relations between recorded severe mental illness, 
challenging behaviour, and prescription of antipsychotic 
drugs in adults with intellectual disability
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 interpretations to include analysis of these variables. We 
did not include our own comparison group without intel-
lectual disability and relied on previously published data 
to put our results in context. Although prescription of 
drugs is well recorded in THIN, we will have missed the 
minority of prescriptions issued in secondary care.
We cannot establish with certainty the indication for 
drug treatment on the basis of THIN data, which may 
have led to errors in classification where a drug has more 
than one use (for example, certain mood stabilisers that 
are also used as anticonvulsants). We infer that in people 
without a record of severe mental illness and with chal-
lenging behaviour, antipsychotics are used to manage 
behaviour, but this might not be the case. Prescriptions 
for antipsychotics that do not seem to be supported by a 
record of severe mental illness are not necessarily inap-
propriate and may be used within guidelines to treat 
complex depression or anxiety disorders, for example.
Clinical implications and future research
Our findings confirm a high rate of prescription of psy-
chotropic drugs to people with intellectual disability in 
UK primary care and show independent associations of 
prescribing of antipsychotics with challenging 
behaviour, autism, dementia, and advancing age. The 
results suggest that these conditions are managed, in 
some instances, with antipsychotic drugs, which will 
often reflect a departure from evidence based clinical 
guidelines. The finding that the magnitude of the asso-
ciation increased when we excluded sleep disorders 
from the code list suggests that antipsychotics are not 
regularly used for sedation at night.
We need to understand why most antipsychotics are 
prescribed to people without a record of severe mental 
illness and why so many people with challenging 
behaviour receive antipsychotics. Limited evidence sug-
gests that certain antipsychotics might be effective in 
treating behavioural disturbance in adults intellectual 
disability comorbid with autism,49  but no evidence 
 supports antipsychotic use in challenging behaviour out-
side this context.7  Use of antipsychotics for challenging 
behaviour in people with intellectual disability is recom-
mended only under specialist supervision and for short 
periods.24 Antipsychotics may be used where the avail-
ability of other management strategies, such as psycho-
social interventions and communication support, is 
limited. Reducing reliance on drugs will therefore require 
investment in a skilled multidisciplinary team of profes-
sionals who can provide alternative evidence based man-
agement strategies for challenging behaviour.
Excessive use of psychotropic drugs has individual 
and systemic implications. Antipsychotics, in particu-
lar, are associated with several adverse side effects that 
can impair quality of life and lead to deleterious health 
outcomes.50  Reducing the high rate of antipsychotic use 
in people with intellectual disability might help to 
reduce the health inequalities that people with intellec-
tual disability experience, which has been identified as 
a priority area for national action.51 Antipsychotic use in 
people with intellectual disability is complicated by the 
fact that many people will lack the capacity to consent 
to taking drugs. We must ensure that patients and their 
family/carers receive adequate and accessible informa-
tion on the use of psychotropic drugs and are empow-
ered to question drug treatment and seek alternatives. 
On a population scale, unnecessary prescribing of 
drugs burdens health services with avoidable costs, 
both directly in terms of supplying the drug and indi-
rectly in terms of the additional monitoring that pre-
scription of these drugs mandates.
We concentrated our attention in this study on pre-
scribing of antipsychotics to people with intellectual 
disability, given that this has been the focus of most con-
troversy. Future research should explore the appropri-
ateness of prescription of other classes of psychotropic 
drugs in this group. Further investigation of the efficacy 
and safety of psychotropic drugs is needed, particularly 
when they are used for challenging behaviour.
Conclusion
Psychotropic drugs are an important element in the 
management of specific psychiatric conditions. How-
ever, we have shown that adults with intellectual dis-
ability are treated with psychotropic drugs at a rate far 
exceeding that of recorded mental illness and that cer-
tain subgroups (such as those with challenging 
behaviour) are significantly more likely to receive anti-
psychotic drugs. Although the prescription of antipsy-
chotic drugs has declined over the past 15 years, more 
work is clearly needed as prescribing often seems to be 
contrary to the evidence base and clinical guidelines of 
good practice.
Inappropriate use of drug treatment has implications 
for the individual and for healthcare systems. Optimis-
ing drug use is central to improving care outcomes and 
will be achieved by a combination of interventions. 
Adoption of a comprehensive medicines optimisation 
programme, such as that promoted by NHS England 
(www.england.nhs.uk/ourwork/pe/mo-dash/), 
enhanced training of front line professionals, timely 
recognition and accurate diagnosis of mental illness in 
people with intellectual disability, and improved acces-
sibility to and development of alternative therapeutic 
strategies could all contribute to reducing excessive use 
of psychotropic drugs.
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